Heat Biologics Inc (NASDAQ:HTBX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm presently has a $0.75 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price points to a potential upside of 7.28% from the company’s previous […]
